On November 9, 2026, Immuneering Corporation appointed Grant C. Bogle, MBA, to the Board of Directors as a Class III Director. His appointment is part of the company's efforts to enhance its governance with experienced leadership
Who to call at Immuneering, and when
A new leader at Immuneering brings new priorities and often new vendors. The first weeks are when they listen.
An alert the day Immuneering raises, hires an executive or expands, scored against what you sell
The decision-makers there, with verified emails
Who you already know at Immuneering, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Immuneering. With Fundz connected, it knows.
Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce★★★★★4.8/5 on G2
Company Information
Company
Immuneering
Location
245 MAIN STREET, SECOND FLOOR
Cambridge, Massachusetts, United States
About
Immuneering is a clinical-stage oncology company focused on keeping cancer patients alive. The Company is developing an entirely new category of cancer medicines, Deep Cyclic Inhibitors. Immuneering’s lead product candidate, atebimetinib (IMM-1-104), is an oral, once-daily Deep Cyclic Inhibitor of MEK designed to improve durability and tolerability, and expand indications to include MAPK pathway-driven tumors such as most pancreatic cancers. Atebimetinib is currently in a Phase 2a trial in patients with advanced solid tumors including pancreatic cancer. The Company’s development pipeline also includes early-stage programs.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Immuneering changes its leadership, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
CambridgeBiotechnologyHealthcareHealth CareMedicalTherapeutics